Contract analysis

I. Executive Summary This memorandum rebuts the economic analysis prepared by Dr. Alan Washburne of the Internal Revenue Service Transfer Pricing Practice, which underpins the Notice of Proposed Adjustment ("NOPA") issued on October 12, 2023, proposing net transfer pricing adjustments of $380.4 million across tax years 2017 through 2020 against Penterra Pharmaceuticals Corp. ("PPC"). Whitmore Valuation Group LLC ("Wh

1. Comparable Uncontrolled Transaction ("CUT") Selection Criteria for the Royalty Rate Analysis. Dr. Washburne's selection of purported CUT agreements fails to satisfy the comparability standards prescribed by Treasury Regulation § 1.482-4(c). His comparable set includes license agreements involving fundamentally non-comparable intangible property — specifically, platform technology licenses with broad sublicensing r

3. Projected Revenue Growth Rates Used to Derive Reasonably Anticipated Benefit ("RAB") Shares for the CSA Cost-Sharing Analysis. Dr. Washburne's RAB recalculation improperly incorporates ex post actual results rather than ex ante prospective projections, overstates Americas revenue projections by including revenue from products and indications not covered by the CSA, and applies compound annual growth rates that exc

II. Background and Scope of Engagement A. Whitmore Valuation Group's Engagement Whitmore Valuation Group LLC was retained by Calderwood & Harkness LLP under a Kovel arrangement, pursuant to an engagement letter dated June 20, 2022 (Reference: 1018-00009-KV). Under this arrangement, Whitmore serves as a consulting expert engaged by counsel at the direction of PPC's legal team, and all communications, work product, and

1. CUT-Based Royalty Rate Increase. Dr. Washburne proposes increasing the legacy IP royalty rate from PPC's 4.5% to 11.0% of non-Americas net sales, based on a set of purported CUT agreements that he asserts establish an arm's-length royalty rate.

2. Income-Method PCT Revaluation. Dr. Washburne revalues the PCT payment at $852 million (versus PPC's $312 million) using the income method under Treasury Regulation § 1.482-7(g)(4), applying a WACC of 7.2% and aggressive revenue growth projections.

3. RAB-Based CSA Cost-Sharing Ratio Increases. Dr. Washburne proposes increasing PBI's cost-sharing percentages by 8 to 12 percentage points per year for each of the four examination years, resulting in additional cost-sharing payments totaling $235.01 million.

4. Partial Economic Substance Challenge. Dr. Washburne asserts that PBI lacks sufficient economic substance to justify its role as IP owner and CSA participant, arguing that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation) remained in the United States. Each of these elements is addressed and rebutted in detail in the sections that follow.

III. Rebuttal of Dr. Washburne's CUT Analysis — Legacy IP Royalty Rate A. Summary of Dr. Washburne's Position Dr. Washburne proposes increasing the legacy IP royalty rate from PPC's 4.5% to 11.0% of non-Americas net sales. The 11.0% rate represents a 6.5 percentage point increase over PPC's reported royalty rate. Applied to PBI's non-Americas net sales of the legacy compounds during the four examination years, this i

IV. Rebuttal of Dr. Washburne's PCT Valuation — Discount Rate / WACC Analysis A. Summary of Dr. Washburne's Position Dr. Washburne revalued the platform contribution transaction ("PCT") at $852 million using the income method prescribed by Treasury Regulation § 1.482-7(g)(4). PPC reported a PCT payment of $312 million, paid by PBI to PPC on July 1, 2012, in connection with PBI's acquisition of the right to develop an

V. Rebuttal of Dr. Washburne's CSA Cost-Sharing Ratio Analysis A. Summary of Dr. Washburne's Position Dr. Washburne proposed increasing PBI's cost-sharing percentages for each of the four examination years, as follows: Dr. Washburne's proposed increases of 10.0 to 11.2 percentage points per year are based on his recalculation of the RAB shares, in which he asserts that PPC's projections of reasonably anticipated bene

VI. Rebuttal of Dr. Washburne's Economic Substance Assertions A. Summary of Dr. Washburne's Position In addition to his quantitative transfer pricing adjustments, Dr. Washburne asserted in his economic analysis that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant for non-Americas territories. Specifically, Dr. Washburne argued that the key DEMPE functions — Development, En